Does enclomiphene cause hair loss? It is a question increasingly asked by men using this unlicensed selective oestrogen receptor modulator (SERM) to treat secondary hypogonadism. Enclomiphene works by stimulating the body's own testosterone production, but rising testosterone levels can theoretically convert to dihydrotestosterone (DHT) — a known driver of male-pattern baldness. Current clinical trial data have not established a definitive causal link between enclomiphene and hair loss, yet the theoretical risk is real for genetically predisposed individuals. This article examines the evidence, explores contributing factors, and outlines when to seek medical advice.

Enclomiphene and Hair Loss: What the Evidence Shows

No definitive causal link between enclomiphene and hair loss has been established in published literature; the theoretical risk arises from elevated testosterone converting to DHT, which can accelerate androgenetic alopecia in genetically predisposed men.

Not sure if this is normal? Chat with one of our pharmacists →

Enclomiphene is a selective oestrogen receptor modulator (SERM) and the trans-isomer of clomifene citrate. It works by blocking oestrogen receptors in the hypothalamus and pituitary gland, which stimulates the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). This hormonal cascade encourages the testes to produce more testosterone naturally, making enclomiphene a candidate treatment for secondary hypogonadism in men.

Importantly, enclomiphene has no MHRA marketing authorisation in the UK. Any use in the UK is therefore as an unlicensed medicine, which must be supplied through a regulated prescriber and pharmacy. Because it is unlicensed, large-scale, long-term clinical trial data examining its full side-effect profile — including effects on hair — remain limited.

When it comes to hair loss specifically, no definitive causal link between enclomiphene and hair loss has been established in the current published literature. Early-phase studies of enclomiphene in secondary hypogonadism (such as those by Kaminetsky and colleagues) have not identified alopecia as a consistent or statistically significant adverse event. Any association between enclomiphene use and hair changes should therefore be regarded as theoretical or anecdotal at this stage.

The theoretical basis for concern relates to DHT: enclomiphene raises endogenous testosterone levels, and testosterone can be converted peripherally to dihydrotestosterone (DHT) via the enzyme 5-alpha reductase. DHT is a well-recognised driver of androgenetic alopecia (male-pattern baldness) in genetically predisposed individuals. This means that, while enclomiphene itself may not directly cause hair loss, the hormonal changes it induces could theoretically accelerate hair thinning in those already susceptible — a hypothesis-based risk that is patient-dependent and should be discussed with a prescribing clinician before starting treatment.

Hair Loss as a Reported Side Effect: How Common Is It?

Hair loss does not appear prominently in enclomiphene clinical trial safety data; anecdotal reports exist, but neither the MHRA nor the EMA has issued specific warnings regarding enclomiphene-induced alopecia.

Hair loss does not appear prominently in the formally documented side-effect profiles from enclomiphene clinical trials to date. Available trial safety data, alongside class-effect data from clomifene citrate (the parent compound), have primarily reported adverse effects including:

Experiencing these side effects? Our pharmacists can help you navigate them →

• Mood changes or irritability

• Headaches

• Gastrointestinal discomfort

• Visual disturbances (a recognised class effect of SERMs, including clomifene)

It should be noted that these adverse effects are drawn from small enclomiphene studies and from clomifene class-effect data; they should not be taken as established rates specific to enclomiphene. Hair thinning or alopecia has been mentioned anecdotally in patient forums and some observational reports, but it has not consistently emerged as a significant adverse event in controlled trial data. This does not mean it cannot occur — rather, it suggests that if hair loss does happen, it may be uncommon or attributable to other concurrent factors.

Because enclomiphene is an unlicensed medicine in the UK, it may be supplied via a regulated private prescriber and a licensed pharmacy (for example, as a 'special' or imported product). Real-world safety data may therefore not be as comprehensively captured as for a fully authorised medicine. Neither the EMA nor the MHRA has issued specific warnings regarding enclomiphene-induced alopecia, in part because no marketing authorisation exists.

Patients who notice hair changes after starting enclomiphene should document the timeline carefully and discuss this with their prescribing clinician. You are also encouraged to report any suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app, as this contributes to broader pharmacovigilance efforts for unlicensed medicines.

Other Factors That May Contribute to Hair Thinning

Hair thinning in men can result from androgenetic alopecia, thyroid dysfunction, nutritional deficiencies, telogen effluvium, or concurrent medications — all of which should be investigated before attributing hair loss to enclomiphene.

Before attributing hair loss solely to enclomiphene, it is essential to consider the broader clinical picture. Hair thinning in men can result from a wide range of causes, many of which may coincide with the period during which enclomiphene is started.

Common contributing factors include:

• Androgenetic alopecia — the most prevalent form of hair loss in men, driven by genetic sensitivity to DHT. If testosterone levels rise with enclomiphene treatment, this may unmask or accelerate pre-existing genetic susceptibility.

• Nutritional deficiencies — low iron or ferritin are well-established contributors to hair shedding. Vitamin D and zinc deficiency may also play a role in some individuals; testing for these is appropriate where there are clinical risk factors or symptoms, rather than routinely. Biotin deficiency is rare in the UK and is not a common cause of hair loss in otherwise healthy adults.

• Thyroid dysfunction — both hypothyroidism and hyperthyroidism can cause diffuse hair loss and should be excluded with a TSH blood test.

• Telogen effluvium — a temporary, stress-induced shedding of hair that can follow illness, significant weight change, surgery, or psychological stress.

• Other medications — concurrent use of anabolic steroids or certain antidepressants may independently affect hair growth cycles. Hair loss after stopping finasteride usually reflects the return of underlying androgenetic alopecia rather than a withdrawal syndrome.

In men being treated for hypogonadism, the underlying hormonal imbalance itself — prior to treatment — may have already disrupted the hair growth cycle. Paradoxically, restoring testosterone levels can sometimes trigger a temporary shedding phase as the body recalibrates.

A thorough medical history and targeted blood tests are advisable before concluding that enclomiphene is the cause of hair changes. In UK primary care, a reasonable initial screen typically includes FBC, ferritin, and TSH; further hormonal or nutritional testing should be guided by clinical history and examination, in line with NICE CKS and Primary Care Dermatology Society (PCDS) guidance on hair loss assessment.

When to Speak to a GP or Specialist About Hair Changes

Seek prompt GP review if hair loss is sudden, patchy, rapidly progressive, or accompanied by scalp inflammation, systemic symptoms, or significant psychological distress.

Not all hair shedding requires urgent medical attention, but certain patterns and associated symptoms warrant prompt review by a GP or specialist. If you are taking enclomiphene and notice hair changes, consider seeking advice if:

• Hair loss is sudden, patchy, or rapidly progressive — this may suggest alopecia areata or another dermatological condition requiring separate investigation.

• The scalp is painful, inflamed, scarred, or shows pustules or crusting — these features may indicate scarring alopecia or a scalp infection and require prompt dermatological assessment.

• Hair thinning is accompanied by other symptoms such as fatigue, weight gain, cold intolerance, or mood disturbance, which could indicate thyroid dysfunction.

• You notice changes to eyebrows, eyelashes, or other body hair, which may point to a systemic cause.

• Hair loss is causing significant psychological distress — this is a valid reason to seek support and review your treatment plan.

In the UK, your first point of contact should be your GP, who can arrange relevant blood tests and refer you to a dermatologist or endocrinologist if needed. Useful UK resources include the NHS Hair Loss page, NICE CKS guidance on alopecia areata and male-pattern hair loss, and patient information from the British Association of Dermatologists (BAD). If enclomiphene has been prescribed privately, ensure your private prescriber is kept informed of any new symptoms.

Do not stop or change your dose of enclomiphene without medical advice. Any decision to adjust or discontinue treatment should be made collaboratively with your prescribing clinician.

Managing Side Effects Safely While Taking Enclomiphene

Attend all scheduled follow-up appointments, ensure relevant blood tests are completed, and consider MHRA-licensed topical minoxidil for confirmed androgenetic alopecia; do not stop enclomiphene without medical advice.

If you are concerned about hair changes while taking enclomiphene, there are several practical and evidence-informed steps you can take to manage this safely.

Monitoring and review: Ensure you attend all scheduled follow-up appointments and blood tests. In line with British Society for Sexual Medicine (BSSM) and Society for Endocrinology guidance on testosterone deficiency, monitoring typically includes total testosterone (with consideration of SHBG and calculated free testosterone), LH, FSH, and prolactin. Thyroid function tests and ferritin should be checked where clinically indicated. Routine measurement of DHT or oestradiol is not standard UK practice unless there is a specific clinical reason; your clinician will advise if additional tests are appropriate. If fertility is a treatment goal, semen analysis may also be relevant.

Lifestyle and nutritional support: A balanced diet rich in protein and micronutrients supports healthy hair growth. Supplementation should only be started if a deficiency has been confirmed by blood tests and on medical advice — routine supplementation with biotin, for example, is not recommended in the absence of a documented deficiency. Avoiding crash diets or extreme caloric restriction is advisable, as these are known triggers for telogen effluvium.

Topical treatments: For those with confirmed androgenetic alopecia, MHRA-licensed topical minoxidil (available as 5% solution or foam) is available over the counter in the UK and has a well-established evidence base for slowing hair loss and promoting regrowth. Full prescribing information is available via the electronic Medicines Compendium (emc) and the NHS Hair Loss page. Topical minoxidil can be used alongside enclomiphene if clinically appropriate, but you should inform your GP or prescriber before starting any new treatment.

Psychological support: Hair loss can significantly affect self-esteem and mental wellbeing. NHS Talking Therapies and support organisations such as Alopecia UK offer resources for those experiencing distress related to hair changes.

If you experience any suspected side effects from enclomiphene, please report them via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Ultimately, any decision to continue, adjust, or stop enclomiphene should always be guided by a qualified clinician who can weigh the benefits of treatment against any emerging side effects in the context of your individual health profile.

Frequently Asked Questions